Video | 08 February 2019 TB survivors challenge J&J's patent on TB drug in India TUBERCULOSIS India Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB. Now they’re working to ensure that this doesn’t happen to anyone else. Read, watch, share Filter by - Any -ExplainerFeature storyIssue briefLetterNewsletterPhoto storyPress releaseReportResearch articleSpeechStatementVideo Letter | 31 July 2023 Tuberculosis Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply Photo credit: Oksana Parafeniuk Press release Press release | 17 July 2023 Tuberculosis MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics 5 min Photo credit: MSF/Alexandra Sadokova Press release Press release | 26 April 2023 Tuberculosis MSF demands J&J give up its patent monopoly on TB drug to put lives over profits 5 min Photograph by Atul Loke Press release Press release | 23 March 2023 Tuberculosis India MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug 4 min Photo credit: MSF/Alexandra Sadokova Press release Press release | 16 January 2023 Tuberculosis India India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline 4 min Photo credit: Oksana Parafeniuk/MSF Press release Press release | 15 December 2022 Tuberculosis MSF responds to groundbreaking updated WHO guidelines for drug-resistant tuberculosis 3 min Photograph by Amelia Freelander Press release Press release | 03 May 2022 Tuberculosis MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB 5 min Photograph by Omar Rashid Research article Research article | 19 April 2022 Tuberculosis BMJ Global Health: Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study 2 min Load More
Letter | 31 July 2023 Tuberculosis Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply
Photo credit: Oksana Parafeniuk Press release Press release | 17 July 2023 Tuberculosis MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics 5 min
Photo credit: MSF/Alexandra Sadokova Press release Press release | 26 April 2023 Tuberculosis MSF demands J&J give up its patent monopoly on TB drug to put lives over profits 5 min
Photograph by Atul Loke Press release Press release | 23 March 2023 Tuberculosis India MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug 4 min
Photo credit: MSF/Alexandra Sadokova Press release Press release | 16 January 2023 Tuberculosis India India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline 4 min
Photo credit: Oksana Parafeniuk/MSF Press release Press release | 15 December 2022 Tuberculosis MSF responds to groundbreaking updated WHO guidelines for drug-resistant tuberculosis 3 min
Photograph by Amelia Freelander Press release Press release | 03 May 2022 Tuberculosis MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB 5 min
Photograph by Omar Rashid Research article Research article | 19 April 2022 Tuberculosis BMJ Global Health: Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study 2 min
